Page 15 - hypertension_newsletter4_Final

REFLECTIONS
Hypertension
Hypertension Global Newsletter #4 2023

PATHOPHYSIOLOGY Hypertension

4. Challenges in the evaluation of endothelial cell dysfunction: A statement from the European Society of
Hypertension Working Group on Endothelin and Endothelial Factors. Rossi GP, et al. Metabolism. 2023
Apr;141 :155402.

BLOOD PRESSURE MEASUREMENT

5. Blood pressure variability: Methodological aspects, clinical relevance and practical indications for management – a
European Society of Hypertension position paper. Parati G, et al. J Hypertens. 2023 Apr 1;41(4):527-544.

6. Higher arm versus lower arm systolic blood pressure and cardiovascular outcomes: A meta-analysis of individual
participant data from the INTERPRESS-IPD collaboration. Clark CE, et al. J Hypertens. 2023 Apr 1;41(4):527-544.
7. Association of home and ambulatory blood pressure with cardiovascular prognosis in practice hypertensive
outpatients. Narita K, et al. J Hypertens. 2023 Apr 1;41(4):527-544.

8. Seasonal variation in blood pressure control across US health systems. Nilles EK, et al. J Hypertens. 2023 Apr
1;41(4):527-544.

TREATMENT

9. The impact of sodium-glucose cotransporter inhibitors on blood pressure: A meta-analysis and metaregression of
111 randomized-controlled trials. Teo YH, et al. J Hypertens. 2023 Apr 1;41(4):527-544.
10. Bedtime dosing of antihypertensive medications: Systematic review and consensus statement: International
Society of Hypertension position paper endorsed by World Hypertension League and European Society of
Hypertension. Stergio G, et al. J Hypertens. 2023 Apr 1;41(4):527-544.

SPECIAL POPULATIONS

11. Cancer therapy-related hypertension: A scientific statement from the American Heart Association. Cohen JB, et al.
Hypertension. 2023 Mar;80(3):e46-e57.

12. Growing heart failure burden of hypertensive heart disease: A call to action. Diez J, Butler J. Hypertension. 2023
Mar;80(3):e46-e57.

13. Risk of target organ damage in children with primary ambulatory hypertension: A systematic review and meta-
analysis. Chung J, et al. Hypertension. 2023;80(6):1183-1196.

ACRONYMS:
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; BP, blood pressure; BPL, blood pressure lowering; cfPWV,
carotid-femoral pulse wave velocity; CHA2DS-VASc, Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes, Stroke
(doubled), Vascular disease, Age 65–74, Sex category (female); cfPWV, carotid-femoral pulse wave velocity; CI, confidence interval;
CKD, chronic kidney disease; CT, computed tomography; CV, cardiovascular; CVD, cardiovascular disease; DBP, diastolic blood
pressure; ECG, electrocardiography; HF, heart failure; HMOD, hypertension-mediated organ damage; HOMA-IR, homeostatic model
assessment for insulin resistance; HR, hazard ratio; HTN, hypertension; LAAO, left atrial appendage occlusion; MI, myocardial
infarction; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oral anticoagulation; OR, odds ratio; PCOS, polycystic ovary
syndrome; PPG, photoplethysmography; RAS, renin-angiotensin system; RCTs, randomized controlled trials; SBP, systolic blood
pressure; SD, standard deviation; SPC, single-pill combination; SR, sustained release; T2DM, type 2 diabetes; TIA, transient
ischemic attack; Tx, open-label prescription.

TABLE OF CONTENTS